Results 111 to 120 of about 71,512 (251)

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

open access: yesEuropean Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese   +12 more
wiley   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

open access: yesEuropean Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello   +7 more
wiley   +1 more source

Extranodal natural killer/T‐cell lymphoma: From fatal to curable

open access: yesCA: A Cancer Journal for Clinicians, Volume 76, Issue 4, July/August 2026.
Abstract Extranodal natural killer (NK)/T‐cell lymphoma (ENKTCL) is one of the most aggressive non‐Hodgkin lymphomas characterized by NK‐cell or T‐cell origins, a geographic prevalence in Asian and South American populations, and Epstein–Barr virus (EBV) infection.
Jie Xiong   +12 more
wiley   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

open access: yesPediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano   +7 more
wiley   +1 more source

QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models. [PDF]

open access: yesMol Cancer Ther
Xie Y   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy